Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAB in their systems.

Now in its third year, the trial is led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and clinical investigators at the University of Pennsylvania. It is funded by the Coronavirus ...

(Registered attendees: Sign in to your USENIX account to download these files.) ...